Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells

International Journal of Cancer

Volumn 129, Issue 8, 2011, Pages 1838-1847

  Hatano, Koji ^a   Miyamoto, Yasuhide ^b   Nonomura, Norio ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

ganglioside; NF B; prostate cancer; sialyltransferase

Indexed keywords

ALPHA 2,3 SIALYLTRANSFERASE I; ALPHA 2,3 SIALYLTRANSFERASE II; ALPHA 2,3 SIALYLTRANSFERASE VI; GANGLIOSIDE; GANGLIOSIDE GD 1A; GANGLIOSIDE GM1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE; SIALYLPARAGLOBOSIDE; SIALYLTRANSFERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LIPOGENESIS; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

CASTRATION; CELL LINE, TUMOR; GANGLIOSIDES; GLOBOSIDES; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIALYLTRANSFERASES; TRANSCRIPTION FACTOR RELB; TRANSCRIPTIONAL ACTIVATION;

EID: 80052036409     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25860     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
2. Isaacs JT,. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263-73. (Pubitemid 29228223)
3. Gulley J, Figg WD, Dahut WL,. Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol 2003; 1: 49-57.
4. Freytag SO, Stricker H, Movsas B, Kim JH,. Prostate cancer gene therapy clinical trials. Mol Ther 2007; 15: 1042-52. (Pubitemid 46813606)
5. Li X, Liu Y, Tang Y, Roger P, Jeng MH, Kao C,. Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. J Gene Med 2010; 12: 516-27.
6. Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL,. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 2010; 17: 805-10.
7. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y,. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 2009; 124: 2478-87.
8. Kurooka M, Kaneda Y,. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007; 1: 227-36. (Pubitemid 46142779)
9. Villar E, Barroso IM,. Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj J 2006; 23: 5-17.
10. Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Portoukalian J, Brosman S, Morton DL,. Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. Biochem Biophys Res Commun 2004; 324: 154-65. (Pubitemid 39311473)
11. Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, Morton DL,. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer 2005; 116: 368-77. (Pubitemid 40993332)
12. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL,. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 1999; 96: 9142-7. (Pubitemid 29374721)
13. Hakomori S,. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996; 56: 5309-18. (Pubitemid 27011703)
14. Taki T, Ishikawa D, Ogura M, Nakajima M, Handa S,. Ganglioside GD1alpha functions in the adhesion of metastatic tumor cells to endothelial cells of the target tissue. Cancer Res 1997; 57: 1882-8. (Pubitemid 27209716)
15. Li R, Liu Y, Ladisch S,. Enhancement of epidermal growth factor signaling and activation of SRC kinase by gangliosides. J Biol Chem 2001; 276: 42782-92.
16. Lang Z, Guerrera M, Li R, Ladisch S,. Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun 2001; 282: 1031-7. (Pubitemid 32924599)
17. Liu Y, Li R, Ladisch S,. Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J Biol Chem 2004; 279: 36481-9. (Pubitemid 39128989)
18. Kanda T, Ariga T, Kubodera H, Jin HL, Owada K, Kasama T, Yamawaki M, Mizusawa H,. Glycosphingolipid composition of primary cultured human brain microvascular endothelial cells. J Neurosci Res 2004; 78: 141-50. (Pubitemid 39305163)
19. Takashima S,. Characterization of mouse sialyltransferase genes: their evolution and diversity. Biosci Biotechnol Biochem 2008; 72: 1155-67. (Pubitemid 351872478)
20. Lee YC, Kojima N, Wada E, Kurosawa N, Nakaoka T, Hamamoto T, Tsuji S,. Cloning and expression of cDNA for a new type of Gal beta 1,3GalNAc alpha 2,3-sialyltransferase. J Biol Chem 1994; 269: 10028-33.
21. Kojima N, Lee YC, Hamamoto T, Kurosawa N, Tsuji S,. Kinetic properties and acceptor substrate preferences of two kinds of Gal beta 1,3GalNAc alpha 2,3-sialyltransferase from mouse brain. Biochemistry 1994; 33: 5772-6. (Pubitemid 24184579)
22. Kono M, Ohyama Y, Lee YC, Hamamoto T, Kojima N, Tsuji S,. Mouse beta-galactoside alpha 2,3-sialyltransferases: comparison of in vitro substrate specificities and tissue specific expression. Glycobiology 1997; 7: 469-79. (Pubitemid 27246720)
23. Okajima T, Fukumoto S, Miyazaki H, Ishida H, Kiso M, Furukawa K, Urano T, Furukawa K,. Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. J Biol Chem 1999; 274: 11479-86.
24. Videira PA, Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, Trindade H, Dall'Olio F,. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 2009; 9: 357.
25. Saito S, Aoki H, Ito A, Ueno S, Wada T, Mitsuzuka K, Satoh M, Arai Y, Miyagi T,. Human alpha2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase. J Biol Chem 2003; 278: 26474-9. (Pubitemid 36876788)
26. Hölschermann H, Stadlbauer TH, Wagner AH, Fingerhuth H, Muth H, Rong S, Güler F, Tillmanns H, Hecker M,. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res 2006; 71: 527-36. (Pubitemid 44107870)
27. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T,. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-9. (Pubitemid 27353450)
28. Korekane H, Tsuji S, Noura S, Ohue M, Sasaki Y, Imaoka S, Miyamoto Y,. Novel fucogangliosides found in human colon adenocarcinoma tissues by means of glycomic analysis. Anal Biochem 2007; 364: 37-50. (Pubitemid 46497950)
29. Weinberg RA, ed. The biology of cancer. New York: Garland Science, Taylor and Francis Group, 2007. 439 p.
30. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, Li Y,. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 2008; 57: 1367-79.
31. Sato H, Kita M, Seiki M,. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993; 268: 23460-8. (Pubitemid 23328072)
32. Abate C, Curran T,. Encounters with Fos and Jun on the road to AP-1. Semin Cancer Biol 1990; 1: 19-26.
33. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL, et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008; 68: 2132-44. (Pubitemid 351521785)
34. Suh J, Rabson AB,. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004; 91: 100-17.
35. Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F,. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005; 93: 1019-23. (Pubitemid 41548396)
36. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 6762-9.
37. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-94.
38. Tsuji S,. Molecular cloning and functional analysis of sialyltransferases. J Biochem 1996; 120: 1-13. (Pubitemid 26258239)
39. Bollrath J, Greten FR,. IKK/NF-kappaB and STAT3 pathways: central signaling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009; 10: 1314-9.
40. Taniguchi A, Yoshikawa I, Matsumoto K,. Genomic structure and transcriptional regulation of human Galbeta1,3GalNAc alpha2,3-sialyltransferase (hST3Gal I) gene. Glycobiology 2001; 11: 241-7. (Pubitemid 32471999)
41. Taniguchi A, Morishima T, Tsujita Y, Matsumoto Y, Matsumoto K,. Genomic structure, expression, and transcriptional regulation of human Gal beta 1,3 GalNAc alpha 2,3-sialyltransferase gene. Biochem Biophys Res Commun 2003; 300: 570-6. (Pubitemid 38375845)
42. Taniguchi A, Kaneta R, Morishita K, Matsumoto K,. Gene structure and transcriptional regulation of human Gal beta1,4(3) GlcNAc alpha2,3- sialyltransferase VI (hST3Gal VI) gene in prostate cancer cell line. Biochem Biophys Res Commun 2001; 287: 1148-56. (Pubitemid 32980572)
43. Higai K, Ishihara S, Matsumoto K,. NFkappaB-p65 dependent transcriptional regulation of glycosyltransferases in human colon adenocarcinoma HT-29 by stimulation with tumor necrosis factor alpha. Biol Pharm Bull 2006; 29: 2372-7. (Pubitemid 44885853)
44. Fusco AJ, Huang DB, Miller D, Wang VY, Vu D, Ghosh G,. NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes. EMBO Rep 2009; 10: 152-9.
45. Britanova LV, Makeev VJ, Kuprash DV,. In vitro selection of optimal RelB/p52 DNA-binding motifs. Biochem Biophys Res Commun 2008; 365: 583-8. (Pubitemid 350181675)
46. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA,. PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int 2009; 104: 556-61.
47. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T,. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-7.
48. Cohen MB, Rokhlin OW,. Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 2009; 106: 363-71.
49. Jiang X, Chen S, Asara JM, Balk SP,. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010; 285: 14980-9.
50. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A, St Clair WH,. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 2009; 69: 3267-71.